Apidra Increased CV Events Likely Due To Baseline Imbalance, FDA Concludes
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The higher incidence of cardiovascular events seen with Sanofi-Aventis’ Apidra in patients with type 1 diabetes appears to have been a result of baseline imbalances, NDA review documents suggest.